Zofenopril calcium
Based on 1 publication(s) in Google Scholar
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.76%
- CAS No.: 81938-43-4
- Formule: C22H22Ca0.5NO4S2
- Masse moléculaire:448.58
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B0279
Ramipril
-
HY-19522
Seladelpar
-
HY-18204
Valsartan
-
HY-B0382
Fosinopril sodium
-
HY-B0231
Enalaprilat dihydrate
-
HY-17005
Olmesartan medoxomil
-
HY-B0592
Trandolapril
-
HY-17005R
Olmesartan medoxomil (Standard)
-
HY-B0477
Quinapril hydrochloride
-
HY-B0368
Captopril
-
HY-B0279R
Ramipril (Standard)
-
HY-18206A
Lisinopril dihydrate
Publications Citing Use of MedChemExpress (MCE) Zofenopril calcium
More
Activité biologique
Zofenopril calcium (30-60 μM; 30 min) decreases oxLDL-induced E-selectin, ICAM-1, and VCAM-1 expressiom in human umbilical vein endothelial (HUVEC) monolayers[1].
Zofenopril calcium (30-60 μM; 30 min) inhibits oxLDL-induced ROS and superoxide formation in HUVECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Zofenopril calcium shows no significant antitumor effect in rat A2780 xenograft model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 81938-43-4
-
Appearance Solid
-
Masse moléculaire 448.58
-
Formule C22H22Ca0.5NO4S2
-
Color White to off-white
-
SMILES
O=C(N(C[C@@H](SC1=CC=CC=C1)C2)[C@@H]2C([O-])=O)[C@H](C)CSC(C3=CC=CC=C3)=O.[0.5Ca2+]
-
Synonyms
SQ26991
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : 2 mg/mL (4.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (622 KB)
- English - EN (622 KB)
- Français - FR (622 KB)
- Deutsch - DE (622 KB)
- Norwegian - NO (622 KB)
- Español - ES (622 KB)
- Swedish - SV (622 KB)
- Italian - IT (622 KB)
- Korean - KR (622 KB)
- Portuguese - PT (622 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cominacini L, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens. 2002 Oct;15(10 Pt 1):891-5. [Content Brief]
[2]. Sacco G, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001 Feb 23;414(1):71-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2293 mL | 11.1463 mL | 22.2926 mL | 55.7314 mL |
Zofenopril calcium Related Classifications
HY-B0655 Related Classifications
Powered by Bioz